Saturday, 20 July 2024

Australia's most trusted
source of pharma news

Saturday, 20 July 2024
Listen to this story 

Combo listed after PBAC mix-up

Posted 2 June 2023 AM

After more than a year of working through challenges posed by a problematic PBAC recommendation, the first PD-1 inhibitor combination treatment for endometrial cancer has been subsidised on the PBS.

MSD's Keytruda in combination with Eisai's Lenvima is now subsidised for eligible women with advanced, metastatic, or recurrent endometrial carcinoma via the PBS as an option following treatment with chemotherapy. If a patient has an intolerance or contraindication to Lenvima, Keytruda can be prescribed as a monotherapy.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (15)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (9)

Other (28)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.